Keywords: straZeneca, Merck & Co, Joint venture, Entocort, Atacand, Plendil

AstraZeneca opts to buy out rights to certain products from US Merck & Co JV for $647 million

Article | 02 March 2010

Print This

Anglo-Swedish drug major AstraZeneca says that it will exercise one of its options under the provisions of the agreements relating ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in